1. Home
  2. PLSM vs KPRX Comparison

PLSM vs KPRX Comparison

Compare PLSM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulsenmore Ltd. Ordinary Shares

PLSM

Pulsenmore Ltd. Ordinary Shares

N/A

Current Price

$1.57

Market Cap

11.6M

Sector

Health Care

ML Signal

N/A

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

N/A

Current Price

$1.57

Market Cap

10.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLSM
KPRX
Founded
2014
1998
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
10.6M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
PLSM
KPRX
Price
$1.57
$1.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.1K
★ 34.4K
Earning Date
08-31-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.62
$1.73
52 Week High
$12.97
$2.91

Technical Indicators

Market Signals
Indicator
PLSM
KPRX
Relative Strength Index (RSI) 26.79 17.48
Support Level N/A N/A
Resistance Level $2.64 $2.19
Average True Range (ATR) 0.16 0.13
MACD 0.01 -0.07
Stochastic Oscillator 0.00 3.92

Price Performance

Historical Comparison
PLSM
KPRX

About PLSM Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: